Refining diagnostics for the improved detection, surveillance, and study of the transmission dynamics of oropouche
Active Grant Awarded
- Award ID
- R01AI201194
- Recipient
-
Asociacion Benefica Prisma UEI R24LH2TXP5Q2
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $693,616
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 4% complete
- Place of performance
- Peru
Award details come from USAspending.gov.
About this award
The National Institute of Allergy and Infectious Diseases, within the Department of Health and Human Services' National Institutes of Health, awarded Grant R01AI201194 to Asociacion Benefica Prisma (Prisma) for $693,616 on September 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The program supports biomedical research and research training in infectious diseases and related areas. Prisma is a Peruvian nongovernmental organization focused on community health and biomedical research.
The award funds a three-aim study of Oropouche virus (OROV) transmission in a high-endemicity area of Peru. Aim 1 characterizes the human disease burden by applying gold-standard and simplified diagnostics in parallel. Aim 2 studies non-human vertebrate populations in a fragmented forest area for evidence of active and prior OROV infection. Aim 3 conducts vector competency studies on local purported arthropod vectors.
For Aim 1, the project will identify a cohort of 100 febrile individuals with OROV viremia through health care-based surveillance and sample them intensively to measure viremia duration, IgM response kinetics, and seroconversion rate. Parallel testing compares RT-PCR with direct antigen testing to evaluate a prototype rapid OROV test, and compares IgM detection by MAC-ELISA with a recombinant ELISA.
The period of performance runs from the September 19, 2026 award date through an ultimate completion date of August 31, 2031. Place of performance is Peru. The assistance type is a grant, and the dollars obligated total $693,616.
Description
- Abstract
- There is a knowledge GAP regarding the disease burden of oropouche (OROV) in humans because of a lack of direct or standardized indirect diagnostics (serological methods) applied to human OROV surveillance in endemic areas. In addition, the identity of non-human vertebrate hosts involved in the sylvatic transmission cycle remain unclear, and systematic studies of OROV vectors are limited and often yield contradictory findings. The long-term goal is to improve the control and limit the transmission of OROV in humans. The overall objective is to obtain absent critical parameters of OROV disease transmission in humans, arthropods, and non-human vertebrate hosts. The central hypothesis is that these critical gaps of transmission dynamics can be filled through the use of improved molecular and serological diagnostic methods in an area of high historical and current OROV disease endemicity through the performance of the following three specific aims: 1) to characterize the human burden of OROV in a hyperendemic setting through the parallel application of gold standard and simplified diagnostics; 2) to systematically study non-human vertebrate populations in a fragmented forest area for evidence of both active and prior OROV infection; and 3) to conduct vector competency studies on local purported arthropod vectors for oropouche. To address the first specific aim, we will conduct health care-based surveillance to identify a cohort of 100 febrile individuals with OROV viremia. This cohort of OROV participants will undergo intensive sampling to measure the duration of viremia, the kinetics of IGM response, and the rate of seroconversion following infection. Parallel testing of RT-PCR and direct antigen testing will evaluate a prototype of a rapid test for OROV. Additionally, parallel testing of IGM by MAC-elisa and a recombinant elisa will determine if a more scalable serologic test is non-inferior. Finally, a recombinant elisa test will be compared to traditional plaque reduction neutralizing tests (PRNT) as well as a novel, safe and scalable neutralization tests based on a fluorescent and luminescent assay. To address the second aim, we will systematically capture and measure prevalence of prior infection in sylvatic and urban birds, rodents, and small mammals and test non- human primates and other sylvatic species recovered through a partnership with the peruvian organization that recovers trafficked wild animals. For the third aim, we will test a subset of the local vectors culicoides paraensis, culicoides insignisus, aedes serratus, and mansonella venezuelensis for vector competence using standardized membrane feeds of a local and a reference strain of OROV. The proposed research is innovative in use and evaluation of a direct antigen test, and recombinant and scalable serodiagnostics and their application to identify local non-human vertebrate reservoirs. The proposed project is significant in its comprehensive and critical evaluation of scalable, improved diagnostic testing for both acute diagnosis and confirmatory neutralization assays, and their application in an endemic setting to accurately measure disease burden and understand the transmission dynamics of this emerging arboviral disease.
Quick answers
Who received award R01AI201194?
R01AI201194 was awarded to Asociacion Benefica Prisma by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 19, 2026.
How much is award R01AI201194 worth?
$693,616 has been obligated on R01AI201194.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award